Bioheart and PharmaCell Open GMP Lab Facility in Europe to Support Adult Stem Cell Research
This new lab is an advanced research facility that also has GMP cell production capabilities to support research related to Bioheart’s adult muscle stem cell technology.
Article
Novocell, Juvenile Diabetes Research Foundation Announce Partnership to Clinically Test Encapsulated Human Islets
The Juvenile Diabetes Research Foundation announced today that it has established a partnership with Novocell, Inc., an Irvine, California-based, biotechnology company, to support an on-going proof of principle Phase I/II human clinical trial for Novocell’s polyethylene glycol encapsulation of insulin-producing islets.
Article
BioE and University of Newcastle Form Research Partnership to Advance Near-Term Therapeutic Application of Cord Blood Stem Cells
BioE(R), Inc., a biomedical company providing human cord blood stem cells as enabling, high-quality cellular tools for drug discovery and therapeutic research, and the University of Newcastle upon Tyne in England have announced that the two parties have formed a research partnership to advance the near-term therapeutic application of cells derived from human umbilical cord blood, including stem cells.
Article
Medistem Advances Negotiations to License New Stem Cell Laboratories and Clinics in Europe, Asia and North America
Medistem Laboratories, Inc., committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has announced continued progress in its strategic goal to establish a series of international laboratory and clinical facilities to conduct research and fee-for-service treatments employing the Company’s proprietary stem cell-based therapeutic technologies.
Article
Stem Cell Innovations Officially Opened its European R&D Facility in Leiden, The Netherlands Stem Cell Innovations, Inc. has announced that the Company has opened a new R&D facility to commercialise their proprietary platform of human pluripotent stem cells (PCs(TM)) in Europe.
Article
Bristol-Myers Squibb To Build New Biologics Facility In Massachusetts
Bristol-Myers Squibb Company has announced that the company intends to build a new large-scale multi-product bulk biologics manufacturing facility in Devens, Massachusetts, subject to final agreement between the company and the state.
Article
Healtheuniverse Announces Corporate Update; Pursuing New Lab Facilities and Major Pre-Clinical Stem Cell Trials
Healtheuniverse Inc., a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products is pleased to report that progress is being made towards the acquisition of new expanded lab facilities in preparation for a major pre-clinical trial utilizing its proprietary non-embryonic stem cell technology.
Article
ViaCell, Inc. And Children’s Hospital Oakland Research Institute (CHORI) Expand Sibling Cord Blood Donor Program
The combined program brings together CHORI’s nation-wide program and transplant experience with the high quality processing and customer service offered by ViaCord(R), ViaCell’s product offering for the preservation and storage of cord blood for related use.
Article
ViaCell Announces New Office Actions Rejecting PharmaStem Patent Claims
ViaCell, Inc. has announced that, following a re-examination, the United States Patent and Trademark Office (PTO) issued two new office actions rejecting all of the claims of PharmaStem Therapeutics Inc.’s U.S. Patent No. 5,192,553 and U.S. Patent No. 6,569,427 as being unpatentable over prior art.
Article
Oncolytics Biotech Inc. Announces Issuance of 17th U.S. Patent
Oncolytics Biotech Inc. has been granted U.S. Patent 7,052,832 entitled “Methods for the Treatment of Cellular Proliferative Disorders.” The claims describe methods of identifying the susceptibility of cells to reovirus infection.
Article
Ortec International Inc. Obtains First U.S. Patent Allowance On Haptide(TM) Cell Attachment Technology
Haptides(TM), developed at Hapto Biotech, Israel, Ortec’s wholly owned subsidiary, by Drs. Gerard Marx and Raphael Gorodetsky, comprise proprietary synthetic peptides that mimic the mechanism by which cells attach to the blood clot protein, fibrinogen, and can improve the activity of a variety of biomaterials by accelerating the attachment of cells.
Article
Does the Wisconsin Alumni Research Foundation’s European Stem Cell Patent Application Have a Realistic Chance for Approval?
Wisconsin Alumni Research Foundation’s application seeks patent protection for a purified preparation of primate and human embryonic stem cells. The European Patent Office’s Examining Division rejected the application in 2004; however, WARF has appealed this ruling.
Article
Patent Experts Criticize Streamlining Proposal
Increasing backlogs at the U.S. Patent Office are a longstanding frustration for biotech executives. But they said a new set of proposals meant to reduce the waiting time will not provide much relief.
Article
Dr. Gabor Rubanyi Of Berlex Biosciences Joins Cardium Therapeutics, Inc. As Chief Scientific Officer
Cardium Therapeutics, Inc. announced today the appointment of Gabor M. Rubanyi, M.D., Ph.D. as Chief Scientific Officer.
Article
China the “Land of Opportunity” for Stem Cell Research
China could be the first country to conduct human stem cell trials and presents a significant opportunity for Western companies who are brave enough to use this risky destination as a place to pursue this potentially lucrative sector of the biotech industry.
Article